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Foam dressings: a review of the literature 
and evaluation of luid-handling capacity 
of four leading foam dressings
T
here is a wide range of dressings classified 
as ‘foam dressings’; however, there can 
be substantial differences in the chemical 
makeup of different foam dressings. Sussman (2010) 
distinguishes foams into two separate groups, those 
being a ‘true foam’ that draws fluid into air spaces, 
or ‘pseudo-foam’ that draws in fluid and physically 
expands as it retains it. True foams contain hydrophilic 
polyurethane foam, whereas pseudo-foams contain 
absorbent materials, such as viscose and acrylate fibres, 
or particles of superabsorbent polyacrylate designed to 
increase fluid handling. 
The management of wound exudate is one of the 
key components of an effective wound dressing and 
the absorbency and permeability of a dressing have an 
impact on its fluid-handling capacity (Thomas, 2010). 
How effectively a dressing manages wound exudate 
affects a number of factors, including the following: Patient quality of lifeCondition of the surrounding skinWear time and healing rates. 
Manufacturers have sought to produce dressings that 
provide optimum conditions at the wound bed, such 
as foam dressings. These are commonly backed with 
semi-permeable polyurethane film or a thin sheet 
of closed cell polyurethane foam. In such dressings, 
wound fluid is initially taken up by the absorbent 
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Posnett and Franks (2008) have calculated that 200,000 people in the UK have a chronic 
wound, with an estimated treatment cost of between £2.3 billion and £3.1 billion per 
year. With an ever-increasing ageing population, it can be assumed that costs associated 
with the management and treatment of wounds will also continue to rise. he Business 
Service Authority (2014) reported that in 2013 between £160 and £185 million was 
spent on wound care dressings within primary care services in England, of which foam 
dressings accounted for £22.6 million of the overall spend. Foam dressings are frequently 
used in wound care to assist with the management of wound exudate, helping to prevent 
maceration of the wound bed, protect the surrounding skin and prevent cross-infection 
caused by strikethrough. he aim of dressings is to provide an optimum environment 
at the interface with the wound bed to promote wound healing. With limited inancial 
resources within health care, the cost-efectiveness of each type of wound dressing is high 
on the agenda. It is, however, important that costs are not considered in isolation; the 
outcomes (general health beneits) associated with interventions (e.g. wound healing and 
reduction in wound pain) must also be taken into account alongside close collaboration 
with the patient, and in some cases the carer (Rippon et al, 2008). his article provides 
a summary of the published literature relating to foam dressings, investigating their 
impact on healing rates, pain on dressing removal, luid-handling capacity and their cost-
efectiveness. It focuses on the independent assessment of the luid-handling capacity of 
eight commonly-prescribed foam dressings: four bordered (Cutimed® Siltec B, Mepilex® 
Border, Allevyn® Life and Tegaderm™ foam adhesive) and four non-bordered (Cutimed® 
Siltec/Cutimed® SiltecPLUS, Mepilex®, Allevyn® Non-Adhesive, and Tegaderm™ foam). 
KEY WORDSExudate 
management Foam dressings Fluid-handling 
capacity Wound pain
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component of the dressing, and some subsequently 
evaporates through the backing film, extending its 
useful life. The film also serves as a barrier to bacteria, 
preventing strikethrough and reducing the risk of 
bacterial contamination.
Foams can be used as a primary or secondary 
dressing on wounds, and can be left in place for up 
to seven days. They can be used on a range of wound 
types, including: Moderate-to-heavily exuding pressure ulcersVenous ulcers (with compression)Pre-tibial lacerations Superficial and cavity woundsInfected ulcersDiabetic foot lesionsSkin tears Skin grafts Donor sites Surgical sites Acute trauma Pilonidal sinuses. 
As with any type of wound product, care is required 
when applying and removing any dressing that has 
adhesive properties if the skin is fragile, particularly 
in the very young, elderly, cachectic and obese. For 
this reason, there is a range of silicone-coated foam 
dressings (e.g. Mepilex) that aim to prevent trauma 
on removal.
PERFORMANCE
Franks et al (2007) undertook a multi-centre 
prospective randomised clinical trial to compare 
Allevyn Hydrocellular and Mepliex® on a sample 
of 156 patients with chronic venous ulceration. 
Patients were randomised from 12 clinical centres 
with a median ulcer size of 4.33 cm2 (range 0.33–
123.10 cm2). After 24 weeks, a total of 100 (64.1%) 
patients had complete ulcer closure, 46 (29.5%) had 
withdrawn from the trial, nine (5.8%) had ulcers 
that remained unhealed and one patient had died. 
Of the patients randomised to Mepilex, 50 out of 75 
(66.7%) had complete ulcer healing compared with 
50 out of 81 (61.7%) on Allevyn. This difference was 
not statistically significant (P=0.521). The hazard 
ratio for healing after adjustment for bandage 
type and trial centre was 1.48 (95% CI 0.87–2.54; 
P=0.15), which only marginally changed following 
adjustment for baseline variables, neither of which 
achieved statistical significance (P=0.16). Withdrawal 
rates were similar between groups, with 23 patients 
(30.7%) leaving the Mepilex group and 23 (28.4%) 
leaving the Allevyn group, of these 14 patients from 
the Allevyn Group and 17 in the Mepilex group 
withdrew due to wound deterioration; other reasons 
for early withdrawal included patient request, lost 
to follow-up, and bandage-related issues. Anderson 
(2002) performed a similar study investigating 118 
randomised patients to receive either a hydrocellular 
foam dressing (Allevyn) or a polyurethane foam 
dressing (Biatian) when used in combination with 
short stretch bandages for patients with venous 
ulcerations. After 8 weeks they found no difference 
in time to healing, with mean time to healing in 
the hydrocellular foam group 5.0 weeks compared 
to 5.2 weeks in the polyurethane foam. Pérez et al 
(2011) conducted an observational study focusing 
on the use of silicone foam dressings (Mepilex Lite) 
in patients who had undergone radiation therapy. 
The main objective of the study was to measure 
healing (defined as complete re-epithelialisation of 
the wound) and injury progression during radiation 
therapy; 20 patients were included in the study and all 
the wounds 20/20 (100%) progressed to full healing 
with the mean total time to healing being 9.5 days 
(range 3–22 days). Secondary objectives were the 
measurement of:
Trauma caused by dressing removalConvenience and comfortThe patient’s aesthetic perception
Trade name Description 
Cutimed Siltec B Polyurethane foam with a non-adhesive silicone wound contact layer, 
super-absorbers above the foam core and an adherent silicone border
Mepilex Soft silicone-faced polyurethane foam
Mepilex Border Self-adhesive soft silicone-faced polyurethane foam island dressing 
Allevyn non-adhesive Hydrophilic polyurethane foam
Allevyn Life Hydrocellular foam with silicone wound contact layer and surrounding 
border
Tegaderm foam Polyurethane foam with non-adherent wound contact layer
Tegaderm foam 
adhesive
Polyurethane foam with non-adherent wound contact layer on an island 
of breathable ilm backing 
Cutimed Siltec Polyurethane foam with a non-adhesive silicone wound contact layer, 
super-absorbers above the foam core
Cutimed SiltecPLUS Polyurethane foam with with a soft-tack silicone wound contact layer and 
super-absorbers above the foam core
Mepilex Polyurethane foam with soft silicone wound contact layer
Allevyn Non adhesive Polyurethane foam with non-adherent wound contact layer
Tegaderm foam Polyurethane foam with non-adherent wound contact layer
Box 1. Foam dressings included in evaluation
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Ease of useAdaptabilityLength of time the dressing stayed in place.
These objectives were all considered important, as 
inadequate treatment of moist/wet radiodermatitis 
may cause treatment discontinuation, with a 
subsequent impact on disease progression. During 
the evaluation of convenience and comfort, patients 
reported that the dressing did not cause trauma 
during application or removal (20/20, 100%); that 
health professionals and family members, who 
occasionally had to provide treatment, found it easy 
to use (20/20, 100%); it adapted easily to difficult-to-
cover areas (20/20, 100%); additional fixation was 
rarely required (20/20, 100%); it relieved some of 
the symptoms associated with radiodermatitis 
(pruritus, stinging, itching and erythema) (20/20, 
100%) and it was preferred to conventional dressings 
(20/20, 100%).
An intervention review examining the use of 
foam dressings for the healing of diabetic foot ulcers 
(Dumville et al, 2011) included six studies containing 
a total of 157 participants. Meta analysis of two of the 
studies found no statistical difference between foam 
dressings and basic wound contact dressings, and 
pooled data from two studies revealed no significant 
difference in ulcer healing between the foam and 
alignate dressings. They concluded that there was no 
research evidence to suggest that foam wound dressings 
are more effective in healing foot ulcers in patients with 
diabetes than other types of dressings; however, they do 
recognise that the trials were very small.
Minimising costs, i.e. the unit cost of each 
dressing and the number of visits (time taken for 
a nurse to dress the wound), and limiting the pain 
associated with dressing change are key priorities 
for all healthcare environments. Allevyn Gentle 
Border Heel was evaluated by Moody and Bielby, 
(2009) on 20 patients; they considered ease of use, 
wear time, fluid-handling, conformability, comfort, 
change in wound characteristics and the condition 
of the peri-wound skin. They concluded that the 
dressing was easy to apply to the hard-to-dress heel 
area, and prevented maceration due to the pooling of 
exudate. Waring et al (2008) compared the adhesive 
properties of Allevyn Adhesive and Mepilex Border 
and evaluated a number of parameters relating 
to trauma. Strips of the dressings were applied to 
the skin of 22 healthy volunteers, and the forces 
required to peel them off were measured 48 and 
72 hours after dressing application. Dressings were 
also applied to the forearms of the participants and 
removed one day after application, when they were 
asked to rate the severity of pain on removal. After 
removal, the dressings were examined by scanning 
electron microscopy and subjected to protein analysis. 
Allevyn Adhesive was associated with a significantly 
higher level of pain on removal than Mepilex Border 
(P<0.001) and analysis of the dressings after removal 
showed clear differences, with significantly less cellular 
material and protein deposits attached to Mepilex. 
This is mainly due to the soft tacky hydrophobic 
nature of silicone dressings in contrast to traditional 
acrylic adhesives 
In another study, Allevyn silicone adhesive shaped 
heel dressing was evaluated on 20 patients (Hampton, 
2010). Based on clinicians’ subjective data, it was 
concluded that the wounds improved, the dressing was 
atraumatic to the wound bed and was easy to remove. 
All of the patients also reported an improvement in the 
level of pain experienced. Similarly, in a multi-centred 
evaluation of Allevyn Gentle with 153 patients from 
six countries, Hurd et al (2009) concluded that 95% of 
patients found the dressing suitable for the wound type, 
and that it achieved good results in conjunction with 
routine clinical practice. In a randomised controlled 
trial, Franks et al (2007) noted that pain improved 
following treatment with both Allevyn Hydrocellular 
and Mepilex dressings (P<0.001), but observed no 
difference between dressings. Furthermore, Bateman 
(2014) undertook a 38-patient evaluation of the 
Cutimed® Siltec range of foam dressings on a variety of 
acute and chronic wounds in a patient group ranging 
in age from one year to 98 years. Due to the success of 
treatment on this moderate number of patients, the 
evaluation was extended to incorporate a further cohort 
of 112 patients, enabling a 150-patient evaluation to be 
analysed. This comprehensive evaluation, which has yet 
to be published, shows positive holistic outcomes in a 
number of aspects, including: 
Exudate containment Maintenance of a moist wound bed Peri-wound skin protectionAtraumatic dressing application and removalPatient and clinician perception Subsequent choice of product. 
No statistical analysis of the results, however, has 
been conducted to date




The fluid-handling capacity, defined as the sum 
of moisture vapour loss plus absorbency, of four 
bordered dressings and four non-bordered dressings 
were compared (Box 1). The size of all pads was the 
same: 10 cm² (internal diameter = 35.7 mm). The 
bordered products were Cutimed Siltec B, Mepilex 
Border, Allevyn Life and Tegaderm™ foam adhesive. 
The non-bordered products were Cutimed Siltec/
Cutimed SiltecPLUS, Mepilex, Allevyn Non-Adhesive, 
and Tegaderm foam. The fluid-handling properties 
of the dressings were examined using SMTL test 
method TM-390 (British Standards Institution, 
2002), which is written in accordance with European 
Standard BS EN 13726:1:2002 (Surgical Materials 
Testing Laboratory, 2002). In this test, samples of 
each dressing were applied to Paddington cups, to 
which were added 20 ml of sodium/calcium chloride 
solution containing 142 mmol/litre of sodium ions 
and 2.5 mmol/litre of calcium ions. The cups were 
weighed to the nearest 0.0001 g using a calibrated 
analytical balance and placed in a temperature- and 
humidity-controlled incubator, which was used to 
maintain an environment of 37±2°C and a relative 
humidity level below 20% for a period of 24 hours. 
At the end of the test, the cups were removed from 
the incubator and allowed to equilibrate at room 
temperature for a period of 30 minutes prior to 
reweighing to the nearest 0.0001 g. The base of each 
cup was then removed, and any remaining fluid was 
allowed to drain. After a period of 15±2 minutes, the 
cup was then reweighed, and the weight of the fluid 
retained by the dressing calculated by difference. The 
loss in weight due to the passage of moisture vapour 
through the dressing was thus determined. For each 
product, five sample measurements were obtained.
The data were summarised descriptively. 
Single-factor analyses of variance (ANOVA) were 
conducted to assess evidence for a difference 
in fluid-handling capacity within the bordered 
dressings. A similar procedure was undertaken 
for the non-bordered dressings. Prior to analysis, 
the suitability of the data for these procedures was 
verified using exploratory data analysis procedures. 
Planned comparisons were undertaken following 
the ANOVA procedure, as an alternative to post 
hoc testing, in which the Cutimed Siltec B and 
Cutimed Siltec/Cutimed SiltecPLUS dressings were 
compared against other dressings (using linear 
contrasts). The value of each individual contrast and 
a corresponding effect size were also calculated.
PATIENT AND CLINICIAN EVALUATION 
A product review was also undertaken exploring 
150 ward-based patients presenting with acute and 
chronic exuding wounds. The proposed benefits 
of a foam dressing were reviewed alongside a pre-
set education regimen for both the patient and 
clinician. The outcomes of the evaluation were 
exudate management, protection of the peri-wound 
skin, atraumatic application and removal, non-
adherence and the benefits of using an information 
leaflet within the dressing regimen. In this study, the 
patients who were referred with exuding wounds 
were recruited over 4 months. Monitoring was over 
a 28-day period or until patient discharge, if earlier. 
Data collection related to patient demographics, 
objectives of therapy, previous treatments used, 
wound status, and patient and clinician experience 
of the product and its education leaflet. Both 
patient and clinician were asked what their highest 
priority of management was at day 1, with options 
being ‘reduction and avoidance of maceration to 
peri-wound skin’, ‘exudate management’ and ‘pain 
at wound site’. The significance and strength of 
the association between personnel (i.e. clinician 
or patient) and their priority was tested using the 
chi-square test for association. Patients and clinicians 
were also asked whether they wished to continue 
using the product they were assigned and whether 
the related education leaflet was helpful.
RESULTS – SMTL
Fluid-handing capacity of bordered dressings
Summary statistics indicated Cutimed Siltec B to 
have a mean fluid-handling capacity between 34% 
and 76% greater than other bordered dressings; 
however, the Cutimed Siltec B values were more 
variable than those of other dressings (Table 1). 
Exploratory analyses confirmed that the data fulfilled 
all necessary assumptions for the statistical testing to 
be undertaken.
The ANOVA test indicated a significant difference 
between products. Planned comparisons indicated 
significant differences between Cutimed Siltec B, and 
each of the other bordered products (P<0.001 in all 
cases). Cutimed Siltec B had a greater fluid-handling 
capacity than the all other tested products, with effect 
sizes being large in all cases. Cutimed Siltec B was also 
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Cutimed Siltec/Cutimed SiltecPLUS 23.8 (1.10)
Mepilex 29.1 (1.03)
Allevyn Non-Adhesive 22.4 (2.22)
Tegaderm foam 10.0 (0.261)
Table 1: Fluid-handling capacity of bordered 
dressings
found to have a significantly greater fluid-handling 
capacity than a combination of the other products 
in a deviance linear contrast, (P<0.001). The fluid-
handling capacities of bordered products and their 
effects, and corresponding significance levels for the 
comparisons, are summarised in Table 2.
Fluid-handing capacity of non-bordered dressings 
summary statistics indicated that Cutimed Siltec/
Cutimed SiltecPLUS had a mean fluid-handling capacity 
of between 18% less than and 138% greater than other 
non-bordered dressings. Cutimed Siltec/Cutimed 
SiltecPLUS exhibited comparable variability to other 
dressings (Table 3). Exploratory analyses confirmed 
that the data fulfilled all necessary assumptions for the 
statistical testing to be undertaken.
The ANOVA test indicated a significant difference 
between products. Planned comparisons indicated 
significant differences between Cutimed Siltec/
Cutimed SiltecPLUS; and Mepilex and Tegaderm Foam. 
Bordered dressing Mean luid-handling 
capacity, g/10 cm (SD) 
Cutimed Siltec B 21.7 (1.68) 
Mepilex Border 16.2 (0.412) 
Allevyn Life 12.3 (0.545) 
Tegaderm foam adhesive 14.0 15.6 (0.498) 00
No significant difference was found between Cutimed 
Siltec/Cutimed SiltecPLUS and Allevyn Non-Adhesive. 
Cutimed Siltec/Cutimed SiltecPLUS exhibited greater 
fluid-handling capacity than the other tested products 
except Mepliex; and also exhibited greater fluid-
handling capacity than a combination of other tested 
products in a deviance linear contrast. 
The fluid-handling capacities of non-bordered 
products, their effect sizes and associated significance 
levels for the comparisons are summarised in Table 4.
RESULTS – CLINICAL EVALUATION
Written information along with verbal explanation 
helps patients and clinicians to make informed 
choices about a product’s benefits, uses and 
application and removal criteria. It also helps in 
deciding whether to continue with or discontinue 
product use. Table 5 summarises the responses to 
questions in the product review that were given 
by clinicians and patients relating to their baseline 
priorities. It may be observed that while clinicians’ 
primarily prioritise exudate management, a much 
higher proportion of patients are concerned about 
pain at the wound site. The association between 
personnel (i.e. clinician and patient) and main priority 
was found to be statistically significant (χ2
(2)
=46.8; 
P<0.001). The magnitude of the effect was moderate, 
as measured by the φ coefficient of 0.559.
Table 6 summarises some of the comments 
provided by patients as part of the wound evaluation.
Products being compared Value1 Efect size P-value
Cutimed Siltec B versus Mepilex Border +5.55 0.954 <0.001 
Cutimed Siltec B versus Allevyn Life +9.44 0.948 <0.001
Cutimed Siltec B versus Tegaderm foam adhesive +6.09 0.951 <0.001
Deviance contrast: Cutimed Siltec B reference +7.02 0.942 <0.001
A positive value indicates a higher fluid-handling capacity exhibited by Cutimed Siltec B
Table 2: Comparison of the luid-handling capacity of bordered products, the size of their efect and 
the associated signiicance level 
Table 3: Fluid-handling capacity of non-
bordered dressings
Mean luid handling capacity, g/10cm, (SD)
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Products being compared Value1 Efect size P-value
Cutimed Siltec/Cutimed SiltecPLUS versus Mepilex –5.33 0.842 <0.001 
Cutimed Siltec/Cutimed SiltecPLUS versus Allevyn Non-Adhesive +1.40 0.379 <0.120
Cutimed Siltec/Cutimed SiltecPLUS versus Tegaderm foam +13.70 0.970 <0.001
Deviance contrast: Cutimed Siltec/Cutimed SiltecPLUS reference +3.26 0.761 <0.001
A positive value indicates a higher fluid handling capacity exhibited by Cutimed Siltec/Cutimed® SiltecPLUS 
Table 4: Comparison of the luid-handling capacity of non-bordered products and the size of their efect 
SUMMARY 
The analysis has shown that Cutimed Siltec B 
exhibits the greatest fluid-handling capacity of the 
tested bordered products. The differences between 
Cutimed Siltec B and other bordered products were 
large in magnitude and statistically significant, despite 
the limited number of replicates used in the testing 
process. Of the non-bordered products, Mepilex 
exhibited the greatest fluid-handling capacity. There 
was a considerable and statistically significant 
difference between Mepilex and Cutimed Siltec/
Cutimed SiltecPLUS. Significant differences between 
Mepilex and other non-bordered products were not 
established directly, but could be inferred from this 
finding, as Cutimed Siltec/Cutimed SiltecPLUS has 
been shown to perform at least as well as other non-
bordered products.
It is disappointing to note from the patient 
evaluation that the priorities of the clinician and 
patient differ greatly, particularly within the remit of 
exudate management and pain at the wound site. This 
is evidenced both by the greater proportion of patients 
indicating pain at the wound site to be a priority, and 
the strength and diversity of comments provided 
Which of the following is the highest priority 
to  you?
Clinicians (n=150) Patients (n=150)
Maceration to periwound skin 30 (20%) 9 (6%)
Exudate management 80 (53.3%) 43 (28.7%)
Pain at wound site 40 (26.7%) 98 (65.3%)
Table 5: Patient and clinician priorities at day 1 
Pain “Before trial patient needed Entonox to help with pain during dressing changes. With this product it no 
longer needed Entonox and didn’t hurt at all after second dressing.” “hose dressings helped my mum’s legs 
in that they didn’t hurt when the nurse took them of.” “he pain around my wound is the worst I have ever 
experienced, I was scared to try a new dressing but glad I did, no pain after the second one, which is great.” “No 
one knows what the pain feels like unless you have the wound yourself.” “No pain on removal and didn’t leave a 
sticky residue on skin.” “With previous dressing pain was 5/5, with this new dressing my pain reduced to 0.” 
Maceration/ 
Comfort 
“Less change and no inconvenience of it leaking.” “Didn’t stick to the scabby areas.” “Feels soft and strong.” “I 
trust the dressing not to stick to my wound.” “No problem on baby’s skin.” “Didn’t cause damage to the red, 
inlamed skin borders.” “he other dressing kept slipping of my sore skin edges, making it worse.”  “Didn’t curl 
up and leak like my other one.” “I could lex my hand and it stayed in place.” “Didn’t move under bandages.” 
“Stays in place better than my other dressings, especially when I walk.” “Dressing sat comfortable around my 
chest drain.” “I like the feel of the dressing, it’s nice and soft.”
Exudate “Patient felt safe and trusted the dressing wouldn’t leak.” “Doesn’t leak like the other one.” “Kept my skin dry.” 
“Less visits to GP practice nurse – could go back to work.” “I chose this dressing because I liked the thickness of 
it, it would hold more water.” 
Table 6: Patients commenting on Cutimed Siltec PLUS and Cutimed Siltec B: “hey said, we listened”: 
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by patients on this subject, with many patients 
commenting favourably on apparently unexpected 
reduction in pain, while greater levels of pain had been 
expected, possibly as a result of previous experience 
of inadequately functioning dressings. The results 
of the product evaluation demonstrated positive 
endpoints for exudate containment, moist wound bed 
maintenance, peri-wound skin healing and protection, 
and atraumatic application/removal. All 150 
patients and clinicians said that they would continue 
with Cutimed SiltecPLUS/Cutimed Siltec B. The 
implementation and evaluation of an absorbent foam 
product in conjunction with an educational leaflet 
tailored to the patient is a welcome addition to the 
ever-changing wound care ‘tool box’, which is essential 
for tissue viability nurses and clinicians alike in the 
challenging arena of exudate management for both 
acute and chronic wounds. The leaflet stayed with the 
patients throughout their journey so they could refer 
back to the product information, and future clinicians 
within their care package could also be updated, 
which aids consistency in care approaches.
The close tripartite relationship between patient, 
healthcare professional and industry as a collaborative 
union is key to ensuring that product evaluations, 
outcomes and subsequent decision-making 
encompasses the wants, needs and preferences of the 
patients to ensure holistic wound care is provided. 
Listening to patients and their carers is vital if product 
production, procurement and availability is to 
positively evolve.
There will always be the need for on-going 
exploration and evaluation of innovative products 
that provide atraumatic application/removal, non-
adherence to the wound bed, adequate absorption 
and moist wound bed maintenance properties. 
These products need to be cost-effective, appeal to 
both the patient and the clinician, and come with 
useful patient information leaflets. However, patients’ 
experience and perceptions should be incorporated 
within this process, enabling our patients to 
collaborate within decision-making processes from 
an informed standpoint. We need to be mindful that 
our patients may not choose the product that has 
been scientifically shown to absorb more fluid in a 
laboratory but one that is comfortable, aesthetically 
pleasing in appearance and from a brand or a 
company with which they have had previous positive 
experiences. Compliance with product usage from a 
healthcare perspective is absolutely paramount to a 
product’s success alongside data from the literature 
and laboratory and evidence of its cost-effectiveness.
CONCLUSION
When clinicians, procurement officers and allied 
healthcare workers are selecting products to be 
included on local wound formularies, the concept of 
foam dressing fluid-handling capacity needs to be 
considered alongside all factors related to wound care 
if the right product for the right patient at the right 
time is to be achieved. W
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